Search Results - Eva M. Goetz
- Showing 1 - 6 results of 6
-
1
-
2
Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants by Lisa Brenan, Aleksandr Andreev, Ofir Cohen, Sasha Pantel, Atanas Kamburov, Davide Cacchiarelli, Nicole S. Persky, Cong Zhu, Mukta Bagul, Eva M. Goetz, Alex B. Burgin, Levi A. Garraway, Gad Getz, Tarjei S. Mikkelsen, Federica Piccioni, David E. Root, Cory M. Johannessen
Published 2016Artigo -
3
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors by Dalia Ercan, Chunxiao Xu, Masahiko Yanagita, Calixte S. Monast, Christine A. Pratilas, Joan Montero, Mohit Butaney, Takeshi Shimamura, Lynette M. Sholl, Elena Ivanova, Madhavi Tadi, Andrew M. Rogers, Claire E. Repellin, Marzia Capelletti, Ophélia Maertens, Eva M. Goetz, Anthony Letai, Levi A. Garraway, Matthew J. Lazzara, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne
Published 2012Artigo -
4
MAP Kinase Pathway Alterations in <i>BRAF</i>-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition by Nikhil Wagle, Eliezer M. Van Allen, Daniel J. Treacy, Dennie T. Frederick, Zachary A. Cooper, Amaro Taylor‐Weiner, Mara Rosenberg, Eva M. Goetz, Ryan J. Sullivan, Deborah Farlow, Dennis C. Friedrich, Kristin Anderka, Danielle Perrin, Cory M. Johannessen, Aaron McKenna, Kristian Cibulskis, Gregory V. Kryukov, Eran Hodis, Donald P. Lawrence, Sheila Fisher, Gad Getz, Stacey Gabriel, Scott L. Carter, Keith T. Flaherty, Jennifer A. Wargo, Levi A. Garraway
Published 2013Artigo -
5
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma by Eliezer M. Van Allen, Vivian Wai Yan Lui, Ann Marie Egloff, Eva M. Goetz, Hua Li, Jonas T. Johnson, Umamaheswar Duvvuri, Julie E. Bauman, Nicolas Stransky, Yan Zeng, Breean R. Gilbert, Kelsey P. Pendleton, Lin Wang, Simion I. Chiosea, Carrie Sougnez, Nikhil Wagle, Fan Zhang, Yu Du, David A. Close, Paul A. Johnston, Aaron McKenna, Scott L. Carter, Todd R. Golub, Gad Getz, Gordon B. Mills, Levi A. Garraway, Jennifer R. Grandis
Published 2015Artigo -
6
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma by Eliezer M. Van Allen, Nikhil Wagle, Antje Sucker, Daniel J. Treacy, Cory M. Johannessen, Eva M. Goetz, Chelsea S. Place, Amaro Taylor‐Weiner, Steven R. Whittaker, Gregory V. Kryukov, Eran Hodis, Mara Rosenberg, Aaron McKenna, Kristian Cibulskis, Deborah Farlow, Lisa Zimmer, Uwe Hillen, Ralf Gutzmer, Simone M. Goldinger, Selma Ugurel, Helen Gogas, Friederike Egberts, Carola Berking, Uwe Trefzer, Carmen Loquai, Benjamin Weide, Jessica C. Hassel, Stacey Gabriel, Scott L. Carter, Gad Getz, Levi A. Garraway, Dirk Schadendorf
Published 2013Artigo
Search Tools:
Related Subjects
Cancer research
Biology
Gene
Genetics
Kinase
MAPK/ERK pathway
Mutant
MEK inhibitor
Medicine
Melanoma
Metastatic melanoma
Vemurafenib
Cell biology
Dabrafenib
Epidermal growth factor receptor
Erlotinib
Mutation
Trametinib
Biochemistry
Cancer
Cell culture
Computational biology
Context (archaeology)
EGFR inhibitors
Effector
Erlotinib Hydrochloride
Exome sequencing
Function (biology)
Gain of function
Gefitinib